share_log

Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (Sac-TMT) at 2024 CSCO Congress

PR Newswire ·  Sep 29 11:33

CHENGDU, China, Sept. 28, 2024 /PRNewswire/ -- From September 25th to 29th, the 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting were held in Xiamen. Experts and scholars in the field of oncology from all over China gathered together to discuss the hotspots at the forefront of clinical practice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) presented multiple clinical research results and progress of TROP2 ADC sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) at the conference.

TNBC

2024 CSCO:Oral report by Academician Binghe Xu
2024 CSCO:Oral report by Prof.Wengfeng Fang
2024 CSCO:Oral report by Pro.Jing Wang
2024 CSCO:Oral report by Dr.Zhuo Yang
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment